Gerhard Hindricks1, Milos Taborsky2, Michael Glikson3, Ullus Heinrich4, Burghard Schumacher5, Amos Katz6, Johannes Brachmann7, Thorsten Lewalter8, Andreas Goette9, Michael Block10, Josef Kautzner11, Stefan Sack12, Daniela Husser13, Christopher Piorkowski13, Peter Søgaard14. 1. Herzzentrum Leipzig, Leipzig, Germany. Electronic address: gerhard.hindricks@medizin.uni-leipzig.de. 2. Department of Internal Medicine I-Cardiology, Faculty of Medicine and Dentistry, Olomouc, Czech Republic. 3. Chaim Sheba Medical Center, Tel-Hashomer, Israel. 4. Praxis Dr Heinrich, Nordhausen, Germany. 5. Herz-und Gefäßklinikum GmbH Bad Neustadt, Bad Neustadt, Germany. 6. Barzilai Medical Center, Ashkelon, Israel. 7. Klinikum Coburg GmbH, Coburg, Germany. 8. Isar Herzzentrum, Munich, Germany. 9. St Vincenz Krankenhaus GmbH, Paderborn, Germany. 10. Klinik Augustinum, Munich, Germany. 11. Institute for Clinical and Experimental Medicine, Prague, Czech Republic. 12. Klinikum Schwabing, Munich, Germany. 13. Herzzentrum Leipzig, Leipzig, Germany. 14. Heart Centre and Clinical Institute, Aalborg University Hospital, Aalborg, Denmark.
Abstract
BACKGROUND: An increasing number of patients with heart failure receiveimplantable cardioverter-defibrillators (ICDs) or cardiac resynchronisation defibrillators (CRT-Ds) with telemonitoring function. Early detection of worsening heart failure, or upstream factors predisposing to worsening heart failure, by implant-based telemonitoring might enable pre-emptive intervention and improve outcomes, but the evidence is weak. We investigated this possibility in IN-TIME, a clinical trial. METHODS: We did this randomised, controlled trial at 36 tertiary clinical centres and hospitals in Australia, Europe, and Israel. We enrolled patients with chronic heart failure, NYHA class II-III symptoms, ejection fraction of no more than 35%, optimal drug treatment, no permanent atrial fibrillation, and a recent dual-chamber ICD or CRT-D implantation. After a 1 month run-in phase, patients were randomly assigned (1:1) to either automatic, daily, implant-based, multiparameter telemonitoring in addition to standard care or standard care without telemonitoring. Investigators were not masked to treatment allocation. Patients were masked to allocation unless they were contacted because of telemonitoring findings. Follow-up was 1 year. The primary outcome measure was a composite clinical score combining all-cause death, overnight hospital admission for heart failure, change in NYHA class, and change in patient global self-assessment, for the intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT00538356. FINDINGS:We enrolled 716 patients, of whom 664 were randomly assigned (333 to telemonitoring, 331 to control). Mean age was 65·5 years and mean ejection fraction was 26%. 285 (43%) of patients had NYHA functional class II and 378 (57%) had NYHA class III. Most patients received CRT-Ds (390; 58·7%). At 1 year, 63 (18·9%) of 333 patients in the telemonitoring group versus 90 (27·2%) of 331 in the control group (p=0·013) had worsened composite score (odds ratio 0·63, 95% CI 0·43-0·90). Ten versus 27 patients died during follow-up. INTERPRETATION: Automatic, daily, implant-based, multiparameter telemonitoring can significantly improve clinical outcomes for patients with heart failure. Such telemonitoring is feasible and should be used in clinical practice. FUNDING: Biotronik SE & Co. KG.
RCT Entities:
BACKGROUND: An increasing number of patients with heart failure receive implantable cardioverter-defibrillators (ICDs) or cardiac resynchronisation defibrillators (CRT-Ds) with telemonitoring function. Early detection of worsening heart failure, or upstream factors predisposing to worsening heart failure, by implant-based telemonitoring might enable pre-emptive intervention and improve outcomes, but the evidence is weak. We investigated this possibility in IN-TIME, a clinical trial. METHODS: We did this randomised, controlled trial at 36 tertiary clinical centres and hospitals in Australia, Europe, and Israel. We enrolled patients with chronic heart failure, NYHA class II-III symptoms, ejection fraction of no more than 35%, optimal drug treatment, no permanent atrial fibrillation, and a recent dual-chamber ICD or CRT-D implantation. After a 1 month run-in phase, patients were randomly assigned (1:1) to either automatic, daily, implant-based, multiparameter telemonitoring in addition to standard care or standard care without telemonitoring. Investigators were not masked to treatment allocation. Patients were masked to allocation unless they were contacted because of telemonitoring findings. Follow-up was 1 year. The primary outcome measure was a composite clinical score combining all-cause death, overnight hospital admission for heart failure, change in NYHA class, and change in patient global self-assessment, for the intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT00538356. FINDINGS: We enrolled 716 patients, of whom 664 were randomly assigned (333 to telemonitoring, 331 to control). Mean age was 65·5 years and mean ejection fraction was 26%. 285 (43%) of patients had NYHA functional class II and 378 (57%) had NYHA class III. Most patients received CRT-Ds (390; 58·7%). At 1 year, 63 (18·9%) of 333 patients in the telemonitoring group versus 90 (27·2%) of 331 in the control group (p=0·013) had worsened composite score (odds ratio 0·63, 95% CI 0·43-0·90). Ten versus 27 patients died during follow-up. INTERPRETATION: Automatic, daily, implant-based, multiparameter telemonitoring can significantly improve clinical outcomes for patients with heart failure. Such telemonitoring is feasible and should be used in clinical practice. FUNDING: Biotronik SE & Co. KG.
Authors: T M Helms; M Stockburger; J O Schwab; G Hindricks; F Köhler; V Leonhardt; A Müller; K Rybak; S Sack; C Zugck; B Zippel-Schultz; C A Perings Journal: Herzschrittmacherther Elektrophysiol Date: 2019-09
Authors: Mateusz Tajstra; Adam Sokal; Arkadiusz Gwóźdź; Marcin Wilczek; Adam Gacek; Konrad Wojciechowski; Elżbieta Gadula-Gacek; Elżbieta Adamowicz-Czoch; Katarzyna Chłosta-Niepiekło; Krzysztof Milewski; Piotr Rozentryt; Zbigniew Kalarus; Mariusz Gąsior; Lech Poloński Journal: Ann Noninvasive Electrocardiol Date: 2016-12-25 Impact factor: 1.468
Authors: Nils Reiss; Thomas Schmidt; Michael Boeckelmann; Sebastian Schulte-Eistrup; Jan-Dirk Hoffmann; Christina Feldmann; Jan D Schmitto Journal: J Thorac Dis Date: 2018-06 Impact factor: 2.895